CN119403554A - 肌萎缩性侧索硬化症的治疗剂或预防剂 - Google Patents

肌萎缩性侧索硬化症的治疗剂或预防剂 Download PDF

Info

Publication number
CN119403554A
CN119403554A CN202380048404.5A CN202380048404A CN119403554A CN 119403554 A CN119403554 A CN 119403554A CN 202380048404 A CN202380048404 A CN 202380048404A CN 119403554 A CN119403554 A CN 119403554A
Authority
CN
China
Prior art keywords
group
atom
tetrahydroquinolin
mmol
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380048404.5A
Other languages
English (en)
Chinese (zh)
Inventor
小川瑞惠
高桥雄大
高垣梢
目黑裕之
浅场绚努涅斯
山本将史
野上摩利菜
辻理一郎
请川直哉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of CN119403554A publication Critical patent/CN119403554A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380048404.5A 2022-06-24 2023-06-23 肌萎缩性侧索硬化症的治疗剂或预防剂 Pending CN119403554A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022101476 2022-06-24
JP2022-101476 2022-06-24
PCT/JP2023/023264 WO2023249106A1 (ja) 2022-06-24 2023-06-23 筋萎縮性側索硬化症の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
CN119403554A true CN119403554A (zh) 2025-02-07

Family

ID=89380133

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380048404.5A Pending CN119403554A (zh) 2022-06-24 2023-06-23 肌萎缩性侧索硬化症的治疗剂或预防剂

Country Status (8)

Country Link
US (1) US20260083723A1 (https=)
EP (1) EP4545079A1 (https=)
JP (1) JPWO2023249106A1 (https=)
KR (1) KR20250026152A (https=)
CN (1) CN119403554A (https=)
AU (1) AU2023286251A1 (https=)
CA (1) CA3256001A1 (https=)
WO (1) WO2023249106A1 (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801593A (en) 1979-09-13 1989-01-31 Burroughs Wellcome Co. Chemotherapeutic agents
JP3209568B2 (ja) 1991-04-16 2001-09-17 杏林製薬株式会社 新規環状アミノフェニル酢酸誘導体、その製造法及びそれらを有効成分とする免疫応答の修飾剤
KR100236910B1 (ko) 1992-12-14 2000-04-01 김영환 고집적 반도체 기억소자의 메모리셀어레이 제조방법
DE10236910A1 (de) 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
ATE507220T1 (de) 2003-12-20 2011-05-15 Merck Patent Gmbh Tetrahydropyranochinolinderivate
DE102005027170A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline
EP2733138B1 (en) * 2011-07-15 2016-09-28 Hamari Chemicals, Ltd. Method for producing optically active tetrahydroquinoline
US20140228420A1 (en) 2011-09-05 2014-08-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
WO2019106434A1 (en) * 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
CN113631535B (zh) * 2019-03-11 2024-04-12 协同医药发展有限公司 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物
CN110372614B (zh) 2019-07-03 2020-09-29 山东师范大学 一种四氢喹喔啉类化合物及制备方法与应用
CN110464727B (zh) 2019-09-06 2025-09-23 山东师范大学 3,4-二氢-2h-苯并-[1,4]恶嗪类药物或其盐在制备抑制铁死亡药物中的应用
IL303307A (en) * 2020-12-25 2023-07-01 Toray Industries Tetrahydroquinoline derivative and its medical use

Also Published As

Publication number Publication date
WO2023249106A1 (ja) 2023-12-28
EP4545079A1 (en) 2025-04-30
AU2023286251A1 (en) 2024-12-05
US20260083723A1 (en) 2026-03-26
JPWO2023249106A1 (https=) 2023-12-28
CA3256001A1 (en) 2025-03-18
KR20250026152A (ko) 2025-02-25

Similar Documents

Publication Publication Date Title
ES2276744T3 (es) Quinolinas y sus derivados nitrogenados sustituidos en posicion 4 con un resto que contiene piperazina y sus uso como agentes antibacterianos.
CN102482221B (zh) 作为katii抑制剂的双环和三环化合物
TW200406410A (en) Compounds
KR102947968B1 (ko) 테트라히드로퀴놀린 유도체 및 그 의약 용도
KR20140041583A (ko) Ｌｒｒｋ2 키나제 활성의 억제제
CA2890003A1 (en) Amine derivatives or salt thereof as tnf"alpha"inhibitors
TW201643140A (zh) ６員雜環衍生物及含有彼等之醫藥組合物
WO2008067644A1 (en) Inhibitors of hiv replication
KR100245955B1 (ko) 메타노안트라센화합물
EP3760633B1 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
GB2370270A (en) Pharmaceutical compounds
JP2009511530A (ja) 抗菌活性を有する５−キノリン誘導体
CN113493449A (zh) No供体香豆素呋咱偶联物及其制药用途
CA2451228A1 (en) Novel heteroaryl derivatives, their preparation and use
CN119403554A (zh) 肌萎缩性侧索硬化症的治疗剂或预防剂
RU2850795C1 (ru) Производное тетрагидрохинолина и его медицинское применение
TWI917519B (zh) 四氫喹啉衍生物及其醫藥用途
WO2023249105A1 (ja) 薬剤性心筋障害の治療剤又は予防剤
HK40096343A (zh) 四氢喹啉衍生物及其医药用途
WO2023249107A1 (ja) 末梢神経障害の治療剤又は予防剤
EP1458703A1 (en) Isochroman compounds for treatment of cns disorders
WO1997032854A1 (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient
JP4324381B2 (ja) Ｔｎｆ活性を有するフェニル−およびピリジル−ピペリジン類
JP2002220386A (ja) ベンジルアミン誘導体、その製法およびその合成中間体
JP2006515606A (ja) アンドロゲン受容体アンタゴニスト

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination